Gilead Sciences (GILD) Gets a Hold from RBC Capital
I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD) with a $120 price target, noting shares closed at $130.86. While Goldman Sachs also issued a Hold, BMO Capital assigned a Buy rating to the stock on July 23.
RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences on July 23 and set a price target of $120.00. The company’s shares closed yesterday at $130.86.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Abrahams is a 5-star analyst with an average return of 14.5% and a 54.40% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Biogen, and Neurocrine.
In addition to RBC Capital, Gilead Sciences also received a Hold from Goldman Sachs’s Salveen Richter in a report issued on July 20. However, on July 23, BMO Capital assigned a Buy rating to Gilead Sciences (NASDAQ: GILD).